



Gimv

Good company for companies

Press release

Antwerp, Munich / 14 April 2010 / 7:30 AM CET

## Gimv continues to increase its presence in German-speaking Europe

- **Expansion of Life Science department in German-speaking Europe**
- **Annegret de Baey-Diepolder joins partner team**

Gimv, the pan-European investment company, is focussing on expanding its investment business in German-speaking Europe as well as its expertise in the Life Sciences sector. With qualified doctor Annegret de Baey-Diepolder on board as a partner the company has gained a reputable expert from the Venture Capital and Life Sciences field.

Annegret de Baey-Diepolder (41) began her professional career as a physician at the Klinik für Dermatologie und Allergologie (clinic for Dermatology and Allergology) of the Munich University. As part of her academic career she took on a Postdoctoral Fellowship at the Institut für Immunologie (institute for Immunology), owned by the company Hoffmann La Roche. In 1999 she started as a Senior Research Group Leader at Micromet AG before moving in 2001 to TVM Capital as an associate where she was appointed a partner in 2006. During her time at TVM she was involved in the Intercell, Jerini, Medigene PIPE and Riemser Arzneimittel AG transactions to name but a few. She also had seats on the supervisory boards of Vivendy, Albireo Pharma and Nitec.

*“With Annegret de Baey-Diepolder on board Gimv has gained an Investment Manager who brings with her a vast wealth of experience in the medical, biotechnology and investment sectors”, says Patrick Van Beneden, Executive Vice President Life Sciences at Gimv, “and she’ll strengthen our investment activities in these areas throughout all financing phases”.*

With its international team Gimv currently has stakes in 20 companies in the Life Sciences sector and is growing rapidly. In the Benelux countries Gimv is already the number 1 in the Life Sciences division. In Germany, Gimv has just invested EUR 19 million in a second financing round in the consortium in JenaValve, a medical-technical company. Patrick Van Beneden still sees *“great growth potential”* in the German-speaking region.

Annegret de Baey-Diepolder shall conduct her business from the Munich site. *“This enables us to continue increasing our local presence in the German-speaking investment market and focus on the Cleantech and Technology divisions which are important to Gimv too”,* concludes Alex Brabers, Executive Vice President at Gimv.



Good company for companies

# Press release

For further information, please contact:

Mr Patrick Van Beneden – Executive Vice President Life Sciences Gimv  
T +32 3 290 21 58 – [patrick.vanbeneden@gimv.com](mailto:patrick.vanbeneden@gimv.com)

Gimv is a European investment company with nearly 30 years of experience in private equity and venture capital. The company is listed on Euronext Brussels and currently manages around EUR 1.8 billion of assets (including third party funds).

Gimv undertakes buyouts and provides growth capital to established companies. Local teams in Belgium, France, The Netherlands and Germany concentrate on these activities. Gimv-XL provides growth financing to larger growth companies in Flanders. Gimv makes venture capital investments in high tech sectors through its specialist teams in Life Sciences, Technology and Cleantech.

Its DG Infra+ fund also focuses on infrastructure projects in the Benelux. For growth capital investments in Russia, Gimv has a joint venture with KBC Private Equity.

For more information about Gimv, please visit our website: [www.gimv.com](http://www.gimv.com)